ProCE Banner Activity

HBV First-line Therapy: How I Choose Among Good Options

Clinical Thought
How do renal dysfunction, insurance coverage, and long-term safety concerns affect whether we should recommend TAF, TDF, or entecavir to our patients starting HBV therapy?

Released: August 17, 2018

Expiration: August 16, 2019

No longer available for credit.

Share

Faculty

Jordan J. Feld

Jordan J. Feld, MD, MPH

Assistant Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Diseases
Sandra Rotman Centre for Global Health
Toronto, Ontario, Canada

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead

Faculty Disclosure

Primary Author

Jordan J. Feld, MD, MPH

Assistant Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Diseases
Sandra Rotman Centre for Global Health
Toronto, Ontario, Canada

Jordan J. Feld, MD, MPH, has disclosed that he has received consulting fees from AbbVie, ContraVir, Gilead Sciences, Janssen, and Merck and funds for research support from Abbott, AbbVie, Gilead Sciences, Janssen, and Merck.